10.22376/ijpbs.2019.10.1.p1-12 Volume 13 Issue 4 October - December Cancer is a serious health issue in all developed countries, and it is second reason of bereavement generally related with people ageing and lifestyle. According to International research in globe on cancer the burden is expected to be 28.4 million cases in 2040. Hence it is important to reduce the cancer burden in the globe by developing innovative treatment options, but many of the today's most novel diagnostic tools, including molecular typing, have empowered improvements in various cancer therapies with better clinical results with high survival rate. But these treatments are of highly expensive and their exclusive rights are estimated to terminate in few years which affects several patients to access better treatment. With increase in cancer health care cost several strategies have been prioritized by united states and around world leading to the development of biosimilars, which have similar biological activity compared to their innovator drug and are often most cost effective and helps the patients to get better treatment and it is considered as a potential solution for cancer therapy. Hence the current review aims to provide a rationalised report on development of biosimilar drugs approved for cancer therapeutics, their economics, regulatory framework, benefits, risks, challenges, major industries involved, quality, safety and efficacy in cancer therapeutics across the globe is discussed. Bharathi Tumkur Ramasetty and Narashima Prasad K Biosimilars, Cancer Therapy, Innovators, Quality, Safety, Efficacy, Regulatory 46-56